Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Farmers Insurance
Fish and Richardson
Cipla
Federal Trade Commission
Johnson and Johnson
Dow
Cantor Fitzgerald
Teva

Generated: November 15, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 210782

« Back to Dashboard

NDA 210782 describes FENOFIBRATE (MICRONIZED), which is a drug marketed by Ajanta Pharma Ltd, Amerigen Pharms Ltd, Apotex Inc, Cnty Line Pharms, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Impax Labs, Invagen Pharms, Mylan Pharms Inc, Rhodes Pharms, and Torrent Pharms Ltd, and is included in twelve NDAs. It is available from nineteen suppliers. Additional details are available on the FENOFIBRATE (MICRONIZED) profile page.

The generic ingredient in FENOFIBRATE (MICRONIZED) is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.
Summary for 210782
Tradename:FENOFIBRATE (MICRONIZED)
Applicant:Torrent Pharms Ltd
Ingredient:fenofibrate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 210782
Medical Subject Heading (MeSH) Categories for 210782
Suppliers and Packaging for NDA: 210782
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FENOFIBRATE (MICRONIZED) fenofibrate CAPSULE;ORAL 210782 ANDA Torrent Pharmaceuticals Limited 13668-438 13668-438-01 100 CAPSULE in 1 BOTTLE (13668-438-01)
FENOFIBRATE (MICRONIZED) fenofibrate CAPSULE;ORAL 210782 ANDA Torrent Pharmaceuticals Limited 13668-438 13668-438-05 500 CAPSULE in 1 BOTTLE (13668-438-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength67MG
Approval Date:Jun 26, 2018TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength134MG
Approval Date:Jun 26, 2018TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength200MG
Approval Date:Jun 26, 2018TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
UBS
Boehringer Ingelheim
Merck
Fish and Richardson
Cerilliant
Medtronic
McKesson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.